Reports

Drug name	NICE TAs	Comments
Cenobamate (Ontozry®)	TA753 - Cenobamate for treating focal onset seizures in epilepsy
Ceritinib	TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer TA395 - Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer	For hospital use only
Certolizumab injection	TA186 - Rheumatoid arthritis - Certolizumab pegol TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed TA574 - Certolizumab pegol for treating moderate to severe plaque psoriasis	Hospital use only
Cetuximab infusion	TA172 - Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck TA145 - Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck TA439 - Cetuximab and panitumumab for previously untreated metastatic colorectal cancer TA118 - Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer TA473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck	National CDF list. For hospital use only.
Chlorambucil tablets	TA344 - Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia TA343 - Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Chlormethine gel	TA720 - Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
Ciclesonide	TA138 - Asthma (in adults) - corticosteroids	Initiation by a respiratory specialist. Supported by a RICaD.
Ciclosporin (Ikervis)	TA369 - Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin 2mg/g eye ointment (Optimmune)	TA369 - Ciclisporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet tablets	TA117 - Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports